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Abstract. An approach to quantitatively image targeted-
agent binding rate in vivo is demonstrated with dual-probe
injection of both targeted and nontargeted fluorescent
dyes. Images of a binding rate constant are created that
reveal lower than expected uptake of epidermal growth
factor in an orthotopic xenograft pancreas tumor 2.3
10−5 s−1, as compared to the normal pancreas 3.4
10−5 s−1. This approach allows noninvasive assess-
ment of tumor receptor targeting in vivo to determine the
expected contrast, spatial localization, and efficacy in
therapeutic agent delivery. © 2010 Society of Photo-Optical Instru-
mentation Engineers. DOI: 10.1117/1.3449109
Keywords: fluorescence; imaging; image processing; molecules; fluo-
rescence spectroscopy; image analysis.
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Targeting therapeutic drugs to tumors based on their over-
expression of cellular receptors is widely researched and has
important clinical success.1,2 Yet there are essentially no good
tools to assess the in vivo receptor expression contrast be-
tween tumor as compared to normal surrounding tissue.3,4 In
tumors with very high molecular signaling such as in the
pancreas,4,5 it is not obvious when a particular receptor is
actually up-regulated as compared to the surrounding normal
tissue versus upregulated without biopsy. Imaging of receptor
status in vivo is problematic, because the majority of any tar-
geted agent in vivo is often not cell-associated yet. Thus, any
single image simply provides a measure of the whole tissue
concentration rather than the bound concentration. Delivery
from the vascular supply to tumor cells requires transvascular
leakage, followed by diffusion through the interstitial space,
and binding to the targeted receptor followed by possible
internalization.6 As such, imaging concentration values in vivo
usually do not provide information about binding,7 since most
of the agent is in the interstitial space. In this work, we dem-
onstrate a new methodology for quantitative imaging of effec-
tive binding rate in vivo, using the difference in fluorescence
signal between a targeted and untargeted agent. We use this to
demonstrate that a tumor known to have high EGFR expres-
sion in vitro5 actually has lower EGF activity than the sur-
rounding normal pancreas in vivo.
Most contrast agent imaging has been interpreted with a
simple pharmacokinetic model that is designed with as few
compartments and rate constants as possible to not overinter-
pret the data. A three compartment model Fig. 1a can be
used effectively to model targeted agent delivery in the tumor,
which includes compartments for 1. the concentration of drug
in the plasma within the vasculature, 2. the concentration in
the interstitial space of the tissue, and 3. the cellular-
associated fraction of drug.7 The dominant fast rates in this
model are transvascular delivery of contrast agent through
rate constant K12, and then cell-associating rate constant due
to binding and uptake, K23. The dominant clearance from the
plasma is given by excretion mechanisms, such as those in the
liver and kidneys, through rate constant Ke. Then the slowest
rates tend to be those involved in backflow from the intersti-
tial space to the vasculature K21, and from the cell-associated
space to the interstitial space K32. Each of these is shown in
the illustration of the model in Fig. 1a.
Based on this linear model, and assuming that backflow
from interstitial space to vasculature K21 is negligible, the
concentrations are related to each other with first-order rate
equations:
v1
dC1
dt
= − Ke + K12v1C1 + v2K21C2, 1
v2
dC2
dt
= + v1K12C1 − v2K23C2 + v3K32C3, 2
v3
dC3
dt
= + v2K23C2 − v3K32C3. 3
Typical values of the concentrations are estimated by solving
Eqs. 1–3 in Fig. 1b using estimates of the K and v values
for the AsPC1 pancreatic adenocarnioma tumor. Using the
simplified compartment model from before, the cell-
association rate constant K23 can potentially be estimated
from the data of overall tissue concentration, given sufficient
accuracy and observables. The problem in accurately estimat-
ing K23 comes in the fact that the effect of K23 is a subtle part
of the overall curve, and it is not obvious that K12 and K23 can
be independently estimated given a single temporal dataset. In
fact, there is quite high sensitivity to K12, but considerably
less sensitivity to K23.
It is important to recognize that data from tissue does not
exactly discriminate the individual compartments C1, C2, and
C3 from each other, as the imaging yields the total signal
weighted by the relative volume fractions where each v is
normalized such that vP+vI+vC=1. For a specific targeted
dye, which is planned to associate with the cellular fraction,
the total tissue concentration, CT is given by the volume frac-
tions multiplied by the concentration of each:
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CTt = v1C1t + v2C2t + v3C3t . 4
If a nonspecific imaging agent is used, it can be assumed that
the cellular associated fraction is equal to zero, such that only
plasma and interstitial fractions are seen and the tissue con-
centration is expressed by:
CNTt = v1C1t + v2C2t . 5
These can be used along with the values of C1, C2, and C3
from before to estimate the expected bulk tissue concentra-
tions, as shown in Fig. 1d. In fact, the difference between
the CT and CNT values Fig. 1d appears very close to the
shape of the curve for the cellular-associated fraction Fig.
1c.
Since the first term in each of these equations is low in the
regions where there are low plasma volume i.e., in bulk tis-
sue without large vessels, then Eqs. 4 and 5 become:
CTt  v2C2t + v3C3t , 6
CNTt  v2C2t . 7
Now from the rate model, some simple approximations can be
used to estimate a value for C3t. Under the assumption that
K32K23, the latter term in Eq. 3 can be ignored, and then
C3t could be defined simply by integration as:
C3t =
v2
v3
K23 C2tdt . 8
These equations lead to the following derivation using the
observed data CT and CNT:
cTt − CNTt
cNTtdt

v3C3
v2C2tdt

K23C2tdt
C2tdt
 K23. 9
Therefore, an estimate of the binding rate constant K23 in vivo
is possible given the signal processing on the left side of Eq.
9. Additionally, the observation that the difference between
the targeted and nontargeted concentrations Fig. 1d looks
qualitatively like the cellular-associated fraction Fig. 1c
makes sense, since this is the numerator in this new Eq. 9.
This nearly linear relationship means that imaging data can
be used to estimate binding, if two dyes can be injected at the
same time, and their fluorescence values used to calculate the
ratio in Eq. 9. To reiterate, the key assumption here is that
the vascular space effect on the signal is minimal, and the
backflow K32 is minimal. This first assumption means that this
approximation will not hold where there are large plasma re-
gions in images, but when volume averaged data are used and
the v1 is low, this approximation should be valid.
The theoretical derivation in Eq. 9 is in terms of the
concentrations of CTt and CNTt, which are not directly
measured. Instead, fluorescence is used, which is linearly pro-
portional to them. In this dual-probe imaging, a key issue is to
normalize for the difference in signal between the targeted
and non targeted dye fluorescence values. As such, we intro-
duce the following approximations, FNTt=ANTCNTt and
FTt=ATCTt, such that we can rewrite Eq. 9 in terms of
the fluorescence intensity values:
BFTt − FNTt
FNTtdt
 K23, 10
where B is defined as B=ANT /AT, the ratio of amplitude val-
ues that accounts for excitation/emission differences in the
two agents as well as any collection efficiencies that are
geometry-specific to the imaging system. This ratio therefore
allows for cancellation of geometric/intensity effects that are
common to both agent signals, and can be estimated by sam-
pling signals from normal tissue. The estimate of K23 from
Eq. 10 can be done at any time point, so it is possible to get
multiple estimates as a function of time. But simulations and
data indicate that the estimate of K23 converges to a value
near 1 h in our case when a significant faction of the targeted
dye is bound, allowing accurate difference estimation in the
numerator.
To test the ability to image K23 directly, AsPC1 xenograft
pancreas tumors were inoculated into mice and imaged in
vivo. The tumors were used when they were a few millimeters
in diameter, and an incision was created in the abdomen and
the pancreas exposed for fluorescence imaging. The targeted
agent used was epidermal growth factor EGF tagged with
IRDye800CW LI-COR Biosciences, Lincoln, Nebraska, and
the nonspecific agent was IRDye700DX by itself. The mice
were intravenously injected with a mixture containing 1 nmol
of each dye 1.3 mM, and imaging was carried out on a
dual-channel flatbed fluorescence scanner Odyssey IR Imag-
ing System, LI-COR Biosciences, Lincoln, Nebraska, which
(c) (d)
(a)
(b)
Fig. 1 Compartment model is shown in a, which includes all the main components of the tumor, including vascular C1, interstitial C2, and
cellular-associated C3 concentrations. The rate constants from transitions are shown along with volume fractions. In b, an estimated table of
values is shown for the pancreas and AsPC-1 xenograft tumor K units are s−1. In c, the rate equations were solved and concentrations for each
compartment are plotted as a function of time. In d, the concentrations for targeted and nontargeted dyes are shown to illustrate what the imaging
data would show.
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allowed sequential imaging of the mice with 685- and
785-nm excitation, and filtering above 700 and 800 nm, re-
spectively. The temporal sequence of images from one mouse
is shown in Fig. 2a for EGF-IRDye800 and Fig. 2b for
IRDye700, with images subscripted 1 through 8 being at ap-
proximately 8-min intervals. These images were then pro-
cessed with each pixel put into Eq. 10, and the resulting K23
image is shown in Fig. 2c. The procedure was repeated for
animals with the two agents 1 EGF-IRDye800 and
IRDye700, and then mice with just nontargeted agents 2
IRDye800 and IRDye700. This latter group was to control for
nonspecific binding of the dye. Calculated images of K23 are
shown in Fig. 3a for two targeted agent mice in the first
group 1 and two control mice in the second group 2. The
images are displayed in color-coded intensity and overlaid on
the fluorescence image of IRDye700 at longer times to help
visualize. It is readily seen that the binding rate values in the
pancreas range from 310−5 to 810−5 s−1, and the
AsPC-1 tumor values range from 210−5 to 510−5 s−1.
Summary whole tissue values are shown in Fig. 3c. Interest-
ingly, this summary data confirms that the binding rate of the
pancreas is higher than that of the tumor, as was expected
from ex vivo analysis.
The value of being able to noninvasively image the bind-
ing rate is apparent from these images, in that the normal
pancreas surrounding the tumor actually has a higher binding
rate than the tumor tissue; yet in vivo biopsy of normal tissue
is rarely done, and so this type of imaging may be critical to
determine when biologically targeted therapy is appropriate.
The studies by Durkin et al.5 indicate there is wide variability
in EGFR expression in pancreas tumor lines and an unknown
level in normal pancreas. The secondary value of the algo-
rithm presented here is to allow accurate quantification of the
effective binding rate in vivo, which can be quantitatively
compared to ex vivo data. This will be important as new thera-
peutics and molecular contrast agents are developed. Perhaps
the only caution in applying this numerical approach is a care-
ful interpretation of the assumptions going into the final equa-
tion. The most inaccurate assumption for tumor imaging
would be the assumption that v1C1tv2C2t+v3C3t,
which is usually true in normal tissue but can be violated if
there are areas of blood pooling. Thus it will be important to
consider elimination of estimates of K23 in these type of re-
gions. Finally, it is important to recognize that this dual-agent
imaging approach might also be extendable to other imaging
modalities where double injection is feasible, through spectro-
scopic separation as was done here, or through sequential
imaging exams.
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Fig. 2 The time sequence of a single mouse imaged every 8 min for a
total of 64 min eight images total, with a the fluorescence from
EGF-labeled with IRDye800CW and b with fluorescence from
IRDye700DX. Then the calculated image of binding K23 is shown in
c as a color plot with units of s−1. Color online only.
Fig. 3 Calculated images of K23 in color, for a two mice with EGF
targeted dye and b two mice with only the control dye without EGF.
The images are overlaid on the intensity fluorescence images to allow
visualization of binding rates in the pancreas white arrow and tumor
black arrow regions. The color bar units are s−1. The summary of
values for tumor, pancreas, and muscle is shown in c for the EGF
and control dyes alone. Color online only.
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